Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field BACKGROUND: The prognosis in childhood non-Hodgkin lymphoma (NHL) has improved dramatically during recent decades. The authors report the results from a 6-year population-based study of cli...
Main Authors: | , , , , , , , |
---|---|
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Lippincott Williams & Wilkins
2010
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/115562 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/115562 |
---|---|
record_format |
openpolar |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/115562 2023-05-15T16:53:06+02:00 Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology Márky, Ildikó Björk, Olle Forestier, Erik Jonsson, Olafur G Perkkiö, Mikko Schmiegelow, Kjeld Storm-Mathiesen, Ingebjorg Gustafsson, Goran Department of Pediatrics, The Queen Silivia Children's Hospital, Göteborg, Sweden. ildiko.marky@pediat.gu.se 2010-09-15 http://hdl.handle.net/2336/115562 en eng Lippincott Williams & Wilkins http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00043426-200409000-00006&LSLINK=80&D=ovft J. Pediatr. Hematol. Oncol. 2004, 26(9):555-60 15342981 http://hdl.handle.net/2336/115562 1077-4114 Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology Adolescent Antineoplastic Combined Chemotherapy Protocols Central Nervous System Neoplasms Child Preschool Disease-Free Survival Female Finland Humans Iceland Immunophenotyping Incidence Lymphoma Non-Hodgkin Male Neoplasm Staging Remission Induction Scandinavia Survival Rate Treatment Outcome Article 2010 ftlandspitaliuni 2022-05-29T08:21:39Z To access publisher full text version of this article. Please click on the hyperlink in Additional Links field BACKGROUND: The prognosis in childhood non-Hodgkin lymphoma (NHL) has improved dramatically during recent decades. The authors report the results from a 6-year population-based study of clinical characteristics and treatment results of NHL from the five Nordic countries. METHODS: All children younger than 15 years of age at diagnosis with NHL diagnosed from 1995 to 2000 were stratified and treated according to immunophenotypic classification and stage of disease. RESULTS: A total of 230 patients were diagnosed with primary NHL, which gives an annual incidence of 0.9/100.000 children, with a median age of 8 years. Seven percent of the children were below 3 years of age at diagnosis. The male/female ratio was 2.3 and was unrelated to age. Patients with pre-B and T-cell NHL constituted 33%, B-cell NHL 53%, and anaplastic large cell lymphoma (ALCL) 14%. According to Murphy's classification, 14% had stage 1, 17% stage 2, 50% stage 3, and 19% stage 4 disease, 12 of whom (28%) had central nervous involvement (CNS) at diagnosis. By January 1, 2003, four children had died during induction, three children died in remission (2, 6, and 26 months from diagnosis), and 24 children experienced a relapse. At 5 years, the probability of event-free survival (p-EFS) was 86+/-2% for all children. The 5-year p-EFS values for stages 1 through 4 were 94%, 97%, 83%, and 79%, respectively. The 5-year p-EFS values were 91% for B-cell, 87% for pre-B, 81% for ALCL, and 79% for T-cell NHL. The 12 patients with CNS involvement at diagnosis had a significantly poorer outcome than stage 4 patients with CNS involvement (p-EFS = 50% vs. 90%, P < 0.01). The 218 patients without CNS disease at diagnosis had a 5-year p-EFS of 88%. CONCLUSIONS: With modern intensive chemotherapy, more than 85% of NHL patients will achieve long-lasting first remission. In the future, preventing death during induction and remission and improving therapy ... Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
Adolescent Antineoplastic Combined Chemotherapy Protocols Central Nervous System Neoplasms Child Preschool Disease-Free Survival Female Finland Humans Iceland Immunophenotyping Incidence Lymphoma Non-Hodgkin Male Neoplasm Staging Remission Induction Scandinavia Survival Rate Treatment Outcome |
spellingShingle |
Adolescent Antineoplastic Combined Chemotherapy Protocols Central Nervous System Neoplasms Child Preschool Disease-Free Survival Female Finland Humans Iceland Immunophenotyping Incidence Lymphoma Non-Hodgkin Male Neoplasm Staging Remission Induction Scandinavia Survival Rate Treatment Outcome Márky, Ildikó Björk, Olle Forestier, Erik Jonsson, Olafur G Perkkiö, Mikko Schmiegelow, Kjeld Storm-Mathiesen, Ingebjorg Gustafsson, Goran Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
topic_facet |
Adolescent Antineoplastic Combined Chemotherapy Protocols Central Nervous System Neoplasms Child Preschool Disease-Free Survival Female Finland Humans Iceland Immunophenotyping Incidence Lymphoma Non-Hodgkin Male Neoplasm Staging Remission Induction Scandinavia Survival Rate Treatment Outcome |
description |
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field BACKGROUND: The prognosis in childhood non-Hodgkin lymphoma (NHL) has improved dramatically during recent decades. The authors report the results from a 6-year population-based study of clinical characteristics and treatment results of NHL from the five Nordic countries. METHODS: All children younger than 15 years of age at diagnosis with NHL diagnosed from 1995 to 2000 were stratified and treated according to immunophenotypic classification and stage of disease. RESULTS: A total of 230 patients were diagnosed with primary NHL, which gives an annual incidence of 0.9/100.000 children, with a median age of 8 years. Seven percent of the children were below 3 years of age at diagnosis. The male/female ratio was 2.3 and was unrelated to age. Patients with pre-B and T-cell NHL constituted 33%, B-cell NHL 53%, and anaplastic large cell lymphoma (ALCL) 14%. According to Murphy's classification, 14% had stage 1, 17% stage 2, 50% stage 3, and 19% stage 4 disease, 12 of whom (28%) had central nervous involvement (CNS) at diagnosis. By January 1, 2003, four children had died during induction, three children died in remission (2, 6, and 26 months from diagnosis), and 24 children experienced a relapse. At 5 years, the probability of event-free survival (p-EFS) was 86+/-2% for all children. The 5-year p-EFS values for stages 1 through 4 were 94%, 97%, 83%, and 79%, respectively. The 5-year p-EFS values were 91% for B-cell, 87% for pre-B, 81% for ALCL, and 79% for T-cell NHL. The 12 patients with CNS involvement at diagnosis had a significantly poorer outcome than stage 4 patients with CNS involvement (p-EFS = 50% vs. 90%, P < 0.01). The 218 patients without CNS disease at diagnosis had a 5-year p-EFS of 88%. CONCLUSIONS: With modern intensive chemotherapy, more than 85% of NHL patients will achieve long-lasting first remission. In the future, preventing death during induction and remission and improving therapy ... |
author2 |
Department of Pediatrics, The Queen Silivia Children's Hospital, Göteborg, Sweden. ildiko.marky@pediat.gu.se |
format |
Article in Journal/Newspaper |
author |
Márky, Ildikó Björk, Olle Forestier, Erik Jonsson, Olafur G Perkkiö, Mikko Schmiegelow, Kjeld Storm-Mathiesen, Ingebjorg Gustafsson, Goran |
author_facet |
Márky, Ildikó Björk, Olle Forestier, Erik Jonsson, Olafur G Perkkiö, Mikko Schmiegelow, Kjeld Storm-Mathiesen, Ingebjorg Gustafsson, Goran |
author_sort |
Márky, Ildikó |
title |
Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
title_short |
Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
title_full |
Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
title_fullStr |
Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
title_full_unstemmed |
Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
title_sort |
intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology |
publisher |
Lippincott Williams & Wilkins |
publishDate |
2010 |
url |
http://hdl.handle.net/2336/115562 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00043426-200409000-00006&LSLINK=80&D=ovft J. Pediatr. Hematol. Oncol. 2004, 26(9):555-60 15342981 http://hdl.handle.net/2336/115562 1077-4114 Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology |
_version_ |
1766043625031991296 |